Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CRBU vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MXCT Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

MXCT Overall Winner 6-Pillar Tally: CRBU 1 – 4 MXCT (1 Tie) Matrix Metrics: CRBU 3 – 5 MXCT

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Caribou Biosciences, Inc. (CRBU) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRBU carries a Unified Composite Score of 46.4/100 (HOLD) at $0.28 (N/M Forward P/E, -1140.6% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Composite vs. Pillar Nuance: While CRBU currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -1140.6% operating margin) and revenue trajectory (+48.7% vs. -26.9% YoY).
  • Technical & Structure Timing Caution: CRBU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.7); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRBU vs MXCT
CRBU NASDAQ
Caribou Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.28
-8.44% 1D
Market Cap $33.5M
TTM Revenue $9.4M
Forward P/E N/M
Beta / 30D Vol 1.56β · 74% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 68.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -39.3%), weak momentum, RSI 21
RSI-14: 20.7 · SMA20: $0.40 · SMA50: $0.72
MXCT NASDAQ Head-to-Head Winner
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (CRBU 1 – 4 MXCT)

Columns: Metric · CRBU · MXCT
1. Valuation Multiples CRBU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.6x 3.9x
2. Growth & Scale MXCT
Revenue Growth (YoY) -26.9% +48.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $9.4M $34M
Market Cap $33.5M $132.2M
3. Profitability & Quality MXCT
Gross Margin N/A 81.0%
Operating Margin -1140.6% -85.5%
Net Profit Margin 0.0% -81.4%
Return on Equity (ROE) -93.8% -16.9%
4. Balance Sheet & Cash Flow MXCT
Cash Generation (TTM) -$105M EBITDA -$24M
Cash Flow Margin N/A -69.2%
Net Cash / Leverage $281,000 Net Debt (0.34x D/E) $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 0.5% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRBU (3) vs MXCT (5)
Institutional Metric CRBU MXCT Criterion Row Edge
Market Capitalization
Scale
$33.5M $132.2M Larger Scale MXCT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-26.9% +48.7% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-1140.6% -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
0.0% -81.4% Higher Margin CRBU
Return on Equity (ROE)
Capital Efficiency
-93.8% -16.9% Higher ROE MXCT
52-Week Range Position
Momentum
0% ($0–$2) 63% ($1–$2) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
1.56β · 74% Vol 1.19β · 96% Vol Lower Realized Risk CRBU
Unified Institutional Score
Composite Signal
46.4 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite CRBU
Trailing 12M Revenue (USD)
Operating Scale
$9.4M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.6x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$105M EBITDA ($281,000 Net Debt (0.34x D/E)) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +45.03 pp
CRBU: -49.23% · MXCT: -4.2%
3M Horizon MXCT +81.22 pp
CRBU: -82.66% · MXCT: -1.44%
6M Horizon MXCT +118.19 pp
CRBU: -86.46% · MXCT: +31.73%
1Y Horizon MXCT +64.97 pp
CRBU: -84.38% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRBU Revenue MXCT Revenue CRBU Op. Margin MXCT Op. Margin Margin Leader
FY2019 $10M $10M -592.7% -93.7% MXCT
FY2020 $10M $20M -292.2% -71.6% MXCT
FY2021 $10M $20M -697.8% -84.3% MXCT
FY2022 $10M $30M -768.2% -95.2% MXCT
FY2023 $30M $20M -336.6% -247.7% MXCT
FY2024 $10M $20M -1667.2% -230.5% MXCT
FY2025 $10M $20M -1329.4% -247.6% MXCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRBU BREAKDOWN
119d in phase · OBV DISTRIBUTION
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CRBU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRBU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $33.5M market capitalization and -1140.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRBU vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over Caribou Biosciences, Inc. (CRBU) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRBU carries a Unified Composite Score of 46.4/100 (HOLD) at $0.28 (N/M Forward P/E, -1140.6% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Composite vs. Pillar Nuance: While CRBU currently prints a higher short-term Unified Composite Score (46.4/100 HOLD vs. MXCT 41.7/100 SELL), MXCT captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-85.5% vs. -1140.6% operating margin) and revenue trajectory (+48.7% vs. -26.9% YoY). Technical & Structure Timing Caution: CRBU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.7); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MXCT leads the Growth & Scale pillar: CRBU posts -26.9% YoY revenue growth and +0.0% YoY earnings growth on $9.4M TTM revenue (N/A gross margin, -1140.6% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), CRBU cumulative revenue shifted +0.0% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, CRBU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

CRBU screens cheaper on headline valuation multiples. CRBU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.6x EV/Revenue (unreported EBITDA margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBU (-93.8% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CRBU carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 74% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.